Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Eli Lilly. Also, EPS is estimated to ramp higher this year by +27.4%.

In its fourth quarter 2024 investor letter, Polen Focus Growth Strategy emphasized stocks such as Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the newly introduced Zepbound Self Pay Journey Program. The company said ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 33 trades. If we consider the specifics of each ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on ...

Magnet Biomedicine announced Friday it has reached a licensing agreement worth up to $1.25B with Eli Lilly (NYSE:LLY) to develop cancer drugs leveraging the company’s TrueGlue discovery platform.

Lilly inked a deal in 2021 with exactly that protein-destroying goal in mind, promising potentially more than $1.6 billion to Lycia Therapeutics to find molecular glues for difficult targets in ...

As the contentious debate over compounded weight loss drugs continues, Eli Lilly is stepping out with an ad campaign ... “You don’t need a prescription, and those government regulators have no hand in ...